

## **REMARKS**

Applicants thank the Examiner for the Final Office Action of May 20, 2009. This Amendment is in full response thereto. Thus, Applicants respectfully request continued examination and allowance of the application.

Claims 7-12 are pending in this application.

### **Entry of Amendment:**

Applicants respectfully request that the instant Amendment be entered by the Examiner. They assert that it does not present a new issue requiring further search and consideration. In response to the Advisory Action, Applicants respectfully assert that the claims as amended do not present indefiniteness. The instant amendment presents claims which recite a post-revamping blast furnace feed fluid consisting of pure oxygen or oxygen diluted with air produced by the cryogenic separation unit wherein the oxygen of purity above 90% by volume of O<sub>2</sub> is fed to the blast furnace in order to obtain over 90% by volume of O<sub>2</sub> in the post-revamping blast furnace feed fluid. This may be accomplished by feeding the oxygen (produced by the cryogenic separation unit) only or be feeding the oxygen (produced by the cryogenic separation unit) diluted with air from the blower.

### **First Claim Rejection Under 35 U.S.C. § 103:**

Claims 7, 8 and 10-12 are rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No 5,582,036 (Drnevich, et al. I) in view of U.S. Patent No 2003/0213688 (Wang, et al.). Applicant respectfully asserts because Drnevich I and Wang, et al., alone or in combination fail to disclose, teach or suggest the claims as amended. Applicant has amended claim 7 to require that the post-revamping blast furnace feed fluid have over 90% by volume of O<sub>2</sub>. On the other hand, Drnevich I discloses oxygen-enriched air of 21-40 mole percent O<sub>2</sub> fed to a blast

furnace. Wang, et al. fails to cure this deficiency. Thus, the rejection should be withdrawn.

**Second Claim Rejection Under 35 U.S.C. § 103:**

Claim 9 is rejected under 35 U.S.C. § 103(a) as being unpatentable over Drnevich I in view of Wang, et al. as applied to claim 7 above, and further in view of U.S. Patent No. 5,802,875 (Drnevich II). Applicant respectfully asserts because Drnevich I and Wang, et al., alone or in combination fail to disclose, teach or suggest the claims as described above and Drnevich II fails to cure the deficiencies of Drnevich I and Wang, et al. Thus, the rejection should be withdrawn.

**CONCLUSION**

Accordingly, it is believed that the present application now stands in condition for allowance. Early notice to this effect is earnestly solicited. Should the examiner believe a telephone call would expedite the prosecution of the application, he/she is invited to call the undersigned attorney at the number listed below.

It is not believed that any fee is due at this time. If that belief is incorrect, please debit deposit account number 01-1375. Also, the Commissioner is authorized to credit any overpayment to deposit account number 01-1375.

Respectfully submitted,

Date: **August 20, 2009**

/Christopher J. Cronin/  
Christopher J. Cronin  
Registration No. 46,513

Air Liquide  
2700 Post Oak Blvd., 18<sup>th</sup> Floor  
Houston, Texas 77056  
Phone: 302-286-5525  
Fax: 713-624-8950